Cosentyx

Vas Narasimhan

Pharma

Novartis increases sales growth estimate through 2029

Backed by the momentum of its current growth drivers, Novartis has adjusted its growth rate expectation from 5%-plus to 6%-plus through 2029.

Kevin Dunleavy Nov 21, 2024 11:57am

UCB tallies another FDA nod for blockbuster hopeful Bimzelx

Nov 20, 2024 10:44am

A small plant growing in a crack in the ground with a shadow of a tree behind it

Biologics gaining ground in HS, but more support needed: Spherix

Nov 11, 2024 11:52am

Novartis

Swiss antitrust regulator drops investigation against Novartis

Oct 10, 2024 9:46am

Novartis Cosentyx Still Working campaign

Novartis' celebrity standbys report Cosentyx is 'Still Working'

May 17, 2024 4:26pm

Narasimhan

Novartis gears up for key expansions of 3 cancer drugs

Apr 23, 2024 3:37pm